文献速递脑血管病

改良Rankin量表与卒中后上肢无力患者恢复表型的关联

Association of Modified Rankin Scale With Recovery Phenotypes in Patients With Upper Extremity Weakness After Stroke.
PubMed 文献 · Neurology · 2022-03-11

该研究纳入73例缺血性卒中后上肢无力患者,在卒中后第一周和90天评估损伤与功能指标,分析其与90天改良Rankin量表(mRS)评分的关系。结果显示损伤和功能结局与90天mRS评分相关,但同一mRS水平内变异很大,且相邻mRS水平间多数指标无差异。mRS不能精确区分损伤和功能差异,也不能充分捕捉有临床意义的改变。

要点

  • 在73例卒中后上肢无力患者中,损伤和功能结局与90天mRS评分相关,但同一mRS水平内变异很大。
  • mRS 2级内上肢Fugl-Meyer评分从8分(接近偏瘫)到66分(无缺陷)不等。
  • mRS 1级与2级间所有结局指标均无差异,Fugl-Meyer和握力在任何相邻mRS级别间均无差异。

核心结论

  • mRS与卒中后特定领域结局广泛相关,证实其在卒中试验中的既定价值,但不能精确区分损伤和功能差异,也不能充分捕捉损伤、日常生活活动状态和移动能力方面有临床意义的改变。
  • 作者认为未来卒中试验中可考虑将详细表型测量与mRS结合使用。

研究设计与样本

  • 研究纳入73例缺血性卒中后上肢无力患者,在卒中后第一周和90天进行损伤和功能测量,分析90天mRS评分与这些结局的关系。

主要发现

  • 在73例患者中,损伤和功能结局与90天mRS评分相关,但同一mRS水平内变异很大:mRS 2级内上肢Fugl-Meyer评分从8分(接近偏瘫)到66分(无缺陷)。
  • 相邻mRS级别间损伤和功能结局总体差异很少;mRS 3级与4级间九孔peg、腿运动、步速、计时起立行走、NIH卒中量表和Barthel指数有显著差异,但mRS 1级与2级间所有结局指标均无差异。
  • Fugl-Meyer和握力在任何相邻mRS级别间均无差异。
  • 大量患者在卒中后前90天内损伤和功能出现有临床意义的改变,但未达到良好mRS结局(mRS评分≤2)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Precise measurement of outcomes is essential for stroke trials and clinical care. Prior research has highlighted conceptual differences between global outcome measures such as the modified Rankin Scale (mRS) and domain-specific measures (e.g., motor, sensory, language or cognitive function). This study related motor phenotypes to the mRS, specifically aiming to determine whether mRS levels distinguish motor impairment and function phenotypes, and to compare mRS outcomes to meaningful changes in impairment and function from acute to subacute recovery after stroke. METHODS: Patients with upper extremity weakness after ischemic stroke were assessed with a battery of impairment and functional measures within the first week and at 90 days after stroke. Impairment and functional outcomes were examined in relation to 90-day mRS scores. Clinically meaningful changes in motor impairment, activities of daily living, and mobility were examined in relation to 90-day mRS score. RESULTS: In this cohort of 73 patients with stroke, impairment and functional outcomes were associated with 90-day mRS scores but showed substantial variability within individual mRS levels: within mRS level 2, upper extremity impairment ranged from near hemiplegia (with an upper extremity Fugl-Meyer score 8) to no deficits (upper extremity Fugl-Meyer score 66). Overall, there were few differences in impairment and functional outcomes between adjacent mRS levels. While some outcome measures were significantly different between mRS levels 3 and 4 (Nine-Hole Peg, Leg Motor, gait velocity, Timed Up and Go, NIH Stroke Scale, and Barthel Index), none of the outcome measures differed between mRS levels 1 and 2. Fugl-Meyer and grip strength were not different between any adjacent mRS levels. A substantial number of patients experienced clinically meaningful changes in impairment and function in the first 90 days after stroke but did not achieve good mRS outcome (mRS score ≤ 2). DISCUSSION: The mRS broadly relates to domain-specific outcomes after stroke, confirming its established value in stroke trials, but it does not precisely distinguish differences in impairment and function, nor does it sufficiently capture meaningful clinical changes across impairment, activities of daily living status, and mobility. These findings underscore the potential utility of incorporating detailed phenotypic measures along with the mRS in future stroke trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Erler KS, Wu R, DiCarlo JA, et al. Association of Modified Rankin Scale With Recovery Phenotypes in Patients With Upper Extremity Weakness After Stroke. Neurology. 2022. PMID: 35277444. doi:10.1212/WNL.0000000000200154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。